• Click on a protocol’s title to view its description in ClinicalTrials.gov.
  • Click on (pdf) to view the protocol (WUSTL key password required).
PI/ContactDiseaseProtocol (Sponsor)Status
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051
Sickle Cell DiseaseSickle Cell Disease Patient Registry (SCDIC-II) (NHLBI)Enrolling
(pdf – password protected)
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051
Sickle Cell DiseaseThe Epidemiology of Silent and Overt Strokes in Adults with Sickle Cell Disease (Global Blood Therapeutics)Enrolling
(pdf – password protected)
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051
Sickle Cell DiseaseSickle Cell Disease and CardiovAscular Risk-Red cell Exchange Trial (SCD-CARRE) (NHLBI)Enrolling
(pdf – password protected)
PI: Elaine Majerus
Contact: Rachel Cody
rcody@wustl.edu
314-362-7306
Hemophilia AA Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients (BioMarin Pharmaceutical)Open
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
Hemophilia AEmicizumab In Patients With Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial (Genetech)Enrollment pending
(pdf – password protected)
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
Hemophilia AEfficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors (Novo Nordisk Pharmaceuticals, Inc.)Open to enrollment
(pdf – password protected)
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
Atypical HUSAtypical Hemolytic-Uremic Syndrome (aHUS) Registry (Alexion)Open to enrollment
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996
Bleeding and clotting disordersCDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders (CDC Division of Blood Disorders)Open
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
PNHParoxysmal Nocturnal Hemoglobinuria (PNH) Registry (Alexion)Open to enrollment
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
PNHA multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan (Novartis)Pending enrollment
(pdf – password protected)
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996
Hemophilia/BleedingAmerican Thrombosis and Hemostasis Network Data Collection (CDC Division of Blood Disorders)Open
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440
Von Willebrand DiseaseA Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD) (American Thrombosis and Hemostasis Network (ATHN))Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
MyelofibrosisExtended Access of Momelotinib in Adults with Myelofibrosis (352-4365) (Gilead)Enrolling by invitation only
(pdf – password protected)
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
MyelofibrosisA Phase 2 Dose Expansion Study of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis (MANIFEST) (Constellation Pharmaceuticals)Ongoing; closed to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
MyelofibrosisPhase 2 Study of KRT-232 in Myelofibrosis Patients Who Failed Prior JAK Inhibitor (Kartos Therapeutics)Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
MyelofibrosisA Phase 1/2 study of INCB000928 ± Ruxolitinib in Myelofibrosis Patients with Anemia (INCB 00928-104) (Incyte Corp)Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Essential ThrombocythemiaA Phase 3 Study of P1101 vs Anagrelide in Essential Thrombocythemia Patients who Failed Hydroxyurea (P1101ET) (PharmaEssentia Corp)Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Essential ThrombocythemiaA Phase 2b Open Label Study of Ropeginterferon (P1101) in Essential Thrombocythemia Patients (PharmaEssentia)Pending Open
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
MyelofibrosisA Phase 3 Study of Pelabresib (CPI-0610) plus Ruxolitinib vs Placebo plus Ruxolitinib in Myelofibrosis Patients (Constellation Pharmaceuticals)Ongoing; closed to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Systemic MastocytosisA Phase 2 Study of CGT9486 in Patients with Nonadvanced Systemic Mastocytosis (Summit) (Cogent Biosciences)Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Systemic MastocytosisA Phase 2 Study of Avapritinib (BLU-285) in Nonadvanced Systemic Mastocytosis Patients with Inadequately Controlled Symptoms (BLU-285-2203) (Blueprint Medicines)Ongoing; closed to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
Polycythemia VeraA Phase 2a Study of ISIS 702843 in Phlebotomy Dependent Polycythemia Vera Patients (ISIS 702843-CS4) (Ionis Pharmaceuticals)Open to enrollment
(pdf – password protected)
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
Polycythemia VeraA Phase 3b Study of Ropeginterferon (P1101) in Polycythemia Vera Patients (PharmaEssentia)Pending Open
(pdf – password protected)
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998
Sickle Cell DiseasePatient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting (National Alliance of Sickle Cell Centers)(pdf – password protected)
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998
Sickle Cell DiseaseGlobin research Network for DATA and Discovery (GRNDaD) (Global Blood Therapeutics)(pdf – password protected)
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998
Sickle Cell DiseaseGlobin research Network for DATA and Discovery (GRNDaD) substudy – HUGS (Global Blood Therapeutics)(pdf – password protected)
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790
Blood clots in cancer patientsA multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effects of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ANT-007) (Anthos Therapeutics)Open to enrollment
(pdf – password protected)
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790
Blood clots in cancer patientsA multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU) cancer associated VTE (ANT-008) (Anthos Therapeutics)Open to enrollment
(pdf – password protected)
PI: Amy Zhou
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
MyelofibrosisA Phase 1b/2a Study of DISC-0974 in Myelofibrosis Patients with Anemia (DISC-0974-102) (DISC Medicine)Pending open
(pdf – password protected)